[1]
|
American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders. 4th Edition, Text Revision. American Psychiatric Press, Washington DC.
|
[2]
|
Birmaher, B., Quintana, H. and Greenhill, L. (1987) Methylphenidate Treatment of Hyperactive Autistic Children. Journal of the American Academy of Child and Adolescent Psychiatry, 26, 248-251.
|
[3]
|
Handen, B.L., Johnson, C.R. and Lubetsky, M. (2000) Efficacy of Methylphenidate among Children with Autism and Symptoms of Attention-Deficit Hyperactivity Disorder. Journal of Autism and Developmental Disorders, 30, 245-255.
http://dx.doi.org/10.1023/A:1005548619694
|
[4]
|
Quintana, H., Birmaher, B., Stedge, D., Lennon, S., Freed, J., Bridge, J. and Greenhill, L. (1995) Use of Methylphenidate in the Treatment of Children with Autistic Disorder. Journal of Autism and Developmental Disorders, 25, 283-294.
http://dx.doi.org/10.1007/BF02179289
|
[5]
|
Research Units on Pediatric Psychopharmacology (RUPP) Autism Network (2005) Randomized, Controlled, Crossover Trial of Metylphenidate in Pervasive Developmental Disorders with Hyperactivity. Archives of General Psychiatry, 62, 1266-1274. http://dx.doi.org/10.1001/archpsyc.62.11.1266
|
[6]
|
Tavakoli, S.A. and Gleason, O.C. (2003) Seizures Associated with Venlafaxine, Methylphenidate, and Zolpidem. Psychosomatics, 44, 262-264. http://dx.doi.org/10.1176/appi.psy.44.3.262
|
[7]
|
Martin, A., Koenig, K., Anderson, G.M. and Scahill, L. (2003) Low-Dose Fluvoxamine Treatment of Children and Adolescents with Pervasive Developmental Disorders: A Prospective, Open-Label Study. Journal of Autism and Developmental Disorders, 33, 77-85. http://dx.doi.org/10.1023/A:1022234605695
|
[8]
|
Adler, L.A., Resnick, S., Kunz, M. and Devinsky, O. (1995) Open-Label Trial of Venlafaxinein Adults with Attention Deficit Disorder. Psychopharmacology Bulletin, 31, 785-788.
|
[9]
|
Carminati, G.G., Deriaz, N. and Bertschy, G. (2006) Low-Dose Venlafaxine in Three Adolescents and Young Adults with Autistic Disorder Improves Self-Injurious Behavior and Attention Deficit/Hyperactivity Disorders (ADHD)-Like Symptoms. Progress in Neuro-Psychopharmacologyand Biological Psychiatry, 30, 312-315.
|
[10]
|
Chong, Y., Harris, R. and Kim, W.J. (1999) Dystonia as a Side Effect of Nonneuroleptics. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 793-795. http://dx.doi.org/10.1097/00004583-199907000-00005
|
[11]
|
Findling, R.L. and Dogin, J.W. (1998) Psychopharmacology of ADHD: Children and Adolescents. Journal of Clinical Psychiatry, 59, 42-49.
|
[12]
|
Findling, R.L., Schwartz, M.A., Flannery, D.J. and Manos, M.J. (1996) Venlafaxine in Adults with Attention-Deficit/ Hyperactivity Disorder: An Open Clinical Trial. Journal of Clinical Psychiatry, 57, 184-189
|
[13]
|
Hedges, D., Reimherr, F.W., Rogers, A., Strong, R. and Wender, P.H. (1995) An Open Trial of Venlafaxine in Adult Patients with Attention Deficit Hyperactivity Disorder. Psychopharmacology Bulletin, 31, 779-783.
|
[14]
|
Hornig, M. (1998) Addressing Comorbidity in Adults with Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychiatry, 59, 69-75.
|
[15]
|
Hornig-Rohan, M. and Amsterdam, J.D. (2002) Venlafaxine versus Stimulant Therapy in Patients with Dual Diagnosis ADD and Depression. Progressin Neuro-Psychopharmacology and Biological Psychiatry, 26, 585-589.
http://dx.doi.org/10.1016/S0278-5846(01)00312-8
|
[16]
|
Kako, Y., Niwa, Y., Toyomaki, A., Yamanaka, H., Kitagawa, N., Denda, K. and Koyama, T. (2007) A Case of Adult Attention-Deficit/Hyperactivity Disorder Alleviated by Milnacipran. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 31, 772-775. http://dx.doi.org/10.1016/j.pnpbp.2006.12.017
|
[17]
|
Krause, K.H., Krause, J. and Trott, G.E. (1998) [Hyperkinetic Syndrome (Attention Deficit-/Hyperactivity Disorder) in Adulthood]. Der Nervenarzt, 69, 543-556. (in German) http://dx.doi.org/10.1007/s001150050311
|
[18]
|
Maidment, I.D. (2003) The Use of Antidepressants to Treat Attention Deficit Hyperactivity Disorder in Adults. Journal of Psychopharmacology, 17, 332-336. http://dx.doi.org/10.1177/02698811030173016
|
[19]
|
Mukaddes, N.M. and Abali, O. (2004) Venlafaxine in Children and Adolescents with Attention Deficit Hyperactivity Disorder. Psychiatry and Clinical Neuroscience, 58, 92-95. http://dx.doi.org/10.1111/j.1440-1819.2004.01199.x
|
[20]
|
Ninan, P.T. (2000) Use of Venlafaxine in Other Psychiatric Disorders. Depression and Anxiety, 12, 90-94.
|
[21]
|
Olvera, R.L., Pliszka, S.R., Luh, J. and Tatum, R. (1996) An Open Trial of Venlafaxine in the Treatment of AttentionDeficit/Hyperactivity Disorder in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology, 6, 241-250. http://dx.doi.org/10.1089/cap.1996.6.241
|
[22]
|
Pary, R., Lewis, S., Matuschka, P.R., Rudzinskiy, P., Safi, M. and Lippmann, S. (2002) Attention Deficit Disorder in Adults. Annals of Clinical Psychiatry, 14, 105-111. http://dx.doi.org/10.3109/10401230209149097
|
[23]
|
Pityaratstian, N. (2005) Advances in Alternative Pharmacotherapy of ADHD. Journal of the Medical Association of Thailand, 88, S357-S362.
|
[24]
|
Pleak, R.R. and Gormly, L.J. (1995) Effects of Venlafaxine Treatment for ADHD in a Child. American Journal of Psychiatry, 152, 1099.
|
[25]
|
Popper, C.W. (1997) Antidepressants in the Treatment of Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychiatry, 58, 14-29.
|
[26]
|
Popper, C.W. (2000) Pharmacologic Alternatives to Psychostimulants for the Treatment of Attention-Deficit/Hyperactivity Disorder. Child and Adolescent Psychiatric Clinics of North America, 9, 605-646.
|
[27]
|
Smith, M.N. (1997) Pharmacologic Properties of Venlafaxine. Journal of Clinical Psychiatry, 58, 178-179.
http://dx.doi.org/10.4088/JCP.v58n0407h
|
[28]
|
Upadhyaya, H.P., Brady, K.T., Sethuraman, G., Sonne, S.C. and Malcom, R. (2001) Venlafaxine Treatment of Patients with Comorbid Alcohol/Cocaine Abuse and Attention-Deficit/Hyperactivity Disorder: A Pilot Study. Journal of Clinical Psychopharmacology, 21, 116-118. http://dx.doi.org/10.1097/00004714-200102000-00025
|
[29]
|
Wilens, T.E., Biederman, J. and Spencer, T.J. (1995) Venlafaxine for Adult ADHD. American Journal of Psychiatry, 152, 1099-1100.
|
[30]
|
Zepf, F.D., Holtmann, M., Stadler, C., Demisch, L., Schmitt, M., Wockel, L. and Poustka, F. (2008) Diminished Serotonergic Functioning in Hostile Children with ADHD: Tryptophan Depletion Increases Behavioral Inhibition. Pharmacopsychiatry, 41, 60-65. http://dx.doi.org/10.1055/s-2007-1004593
|
[31]
|
Gadow, K.D., DeVincent, C.J. and Pomeroy, J. (2006) ADHD Symptom Subtypes in Children with Pervasive Developmental Disorder. Journal of Autism and Development Disorders, 36, 271-283.
http://dx.doi.org/10.1007/s10803-005-0060-3
|
[32]
|
Conners, C.K., Erhardt, D. and Sparrow, E.P. (1999) Technical Manual. Multi-Health Systems, Inc., North Tonawanda.
|
[33]
|
Minzenberg, M.J. (2012) Pharmacotherapy for Attention-Deficit/Hyperactivity Disorder: From Cells to Circuits. Neurotherapeutics, 9, 610-621. http://dx.doi.org/10.1007/s13311-012-0128-7
|
[34]
|
Kolevzon, A., Mathewson, K.A. and Hollander, E. (2006) Selective Serotonin Reuptake Inhibitors in Autism: A Review of Efficacy and Tolerability. Journal of Clinical Psychiatry, 67, 407-414.
http://dx.doi.org/10.4088/JCP.v67n0311
|
[35]
|
Puech, A., Montgomery, S.A., Prost, J.F., Solles, A. and Briley, M. (1997) Milnacipran, a New Serotonin and Noradrenaline Reuptake Inhibitor: An Overview of Its Antidepressant Activity and Clinical Tolerability. International Clinical Psychopharmacology, 12, 99-108. http://dx.doi.org/10.1097/00004850-199703000-00005
|